Biotechnology - Global Outlook

The global outlook series on Biotechnology provides a collection of statistical anecdotes, market briefs, and concise summaries of research findings. The report offers a bird's eye view of the Biotechnology industry. Annotated with 21 fact, and data rich tables the report offers a sneak peek into major end-use industries. Also included is a compilation of all recent mergers, acquisitions, and strategic corporate developments. A regional-level of discussion mirrors the prevalent scenario in key regional markets such as the US, Canada, Mexico, Japan, France, Germany, Poland, UK, Sweden, Switzerland, New Zealand, India, Malaysia, and Brazil, among few others.

The report also includes an indexed, easy-to-refer, fact-finder directory listing the addresses, and contact details of 1,180 companies worldwide.


Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.

For information on site licence pricing please click on Enquire before buying.

BIOTECHNOLOGY
A GLOBAL OUTLOOK, JANUARY 2012


CONTENTS


1. BIOTECHNOLOGY
Global Market Overview
Global Biotechnology Industry Recovers Strongly from Recession
Current and Future Analysis
Table 1: Global Biotechnology Market by Geographic Region - US, Europe, Asia- Pacific and Rest of World with Annual Revenues in US$ million for Years 2010 through 2015

Table 2: Global Biotechnology Market (2011&2015) Percentage Breakdown of Value Sales by Geographic Region - US, Europe, Asia-Pacific and Rest of World

Table 3: Global Biotechnology Market by Product Application - Medical (Therapeutics, Diagnostics and Other Medical Biotech Applications), Biotech Services and Other Biotech
Applications with Annual Revenues in US$ million for Years 2010 through 2015

Table 4: Global Biotechnology Market (2011 & 2015): Percentage Breakdown of Value Sales by Product Application - Medical (Therapeutics, Diagnostics and Other Medical Biotech Applications), Biotech Services and Other Biotech Applications

Table 5: Global Biotechnology Industry (2010): Percentage Breakdown by Funding Type - Public Offering, Venture Funding & Others

Table 6: Leading Countries in Terms of Mergers and Acquisitions in the Biotech Space (2010) Market for “Follow-On” Biologics
Marine Biotechnology
Major Trends
Developing Countries to Emerge as Major Biotech Hubs
Application of Biotechnology Techniques to Rise Tremendously
Biotech Acquisitions Get More Focused
Major M&A Activities
Contract Manufacturing - A New Business otto for Biotechnology Companies
Oncology Dominates Biotech Drugs Sale
Investment on Research: Vital for the Survival of Biotech Companies
Asia-Pacific: A Promising Market for Biopharmaceutical Companies
Biotech Regenerative Medicine Catching On
Reverse Merger Transactions Characterizes the Asian Biotech Sector
Biotech Instrumentation to Speed Up Biotech Research Process
Growth of Bioventure Startups in Japan
Advent of “Mid-Tier” Companies in the Biotech Market
Biogenerics Poised for a Big Entry
Development of DNA Vaccines
Issues Related to Pricing and Reimbursement of Biotech Drugs
End-Use Industries
Overview of Agricultural and Food Biotechnology
Table 7: Acreage of Biotech Crops in US, Argentina, India, Canada, China, Paraguay, Bolivia, Uruguay, Australia, Mexico and Others (2009)
Plants Based Drugs - Innovative Agri Biotech Products
Consolidated Trends
Animal Husbandry and Veterinary Science
Outlook of Health and Medical Biotechnology
Biotech Technologies/Fields of Medical & Health Sector
Bioinformatics
Genomics
Pharmacogenomics
Proteomics
Biochips
Overview of the Biochip Industry
Biochip Technology
Tech Giants Join the Biochip Fray
Biologic Drugs
Cell and Tissue Culture
Market Overview
Proteomics and Pharmacokinetics Drive Market Growth
Regulations Prompt Change in Trends
Biotechnology Instruments
Market Overview
Innovations and Discoveries - Fuel Demand for Biotech
Instrumentation
Biotechnology Reagents
Market Overview
Highly Automated Instrumentation Restricts Use of Reagents
Molecular Biology and Protein Synthesis Reagents are Growing Rapidly

2. MERGERS AND ACQUISITIONS

3. STRATEGIC CORPORATE DEVELOPMENTS

4. PRODUCT LAUNCHES & DEVELOPMENTS

A REGIONAL MARKET PERSPECTIVE

1. NORTH AMERICA

1a. THE UNITED STATES
Overview
Table 8: Fundings for US Biotechnology Industry in 2010
Demand for Biochips to Grow Strongly
Agricultural Biotechnology
Cultivation of GM Crops Rises in US
Biologics - Market Overview
Medical Biotechnology - Market Overview
Table 9: US Pharmaceutical Industry (1996-2010): Number of Drugs Approved by US FDA
Table 10: US Pharmaceutical Industry (2010): Percentage Breakdown of Drug Sales by Type - Generic and Prescription
Table 11: US Healthcare Industry: Projected Expenditure on Healthcare as % of GDP
Table 12: US Pharmaceutical Industry (2010): Top Four Drug Development Biotechnology Companies by Revenues
Table 13: US Pharmaceutical Industry (2010): Percentage Share Breakdown Number of Pipeline Drugs by Indication
Bioinformatics
Proteomics
Biochips
Challenges Faced by US Biotechnology Market

1b. CANADA
Market Overview
Revenues and R&D Expenditures Plunge
Table 14: Canadian Biotechnology Industry (2010): Funds Raised by Biotechnology Clusters

1c. MEXICO
End-Use Industries
Bio-Pharmaceuticals
Food Biotechnology
Environmental Biotechnology

2. JAPAN
Biotechnology Market Overview
Japanese Companies Expand Business Operations
End-Use Industries
Medical Biotechnology and Healthcare
Biosimilars
Food Biotechnology Industry
Environmental Biotechnology

3. EUROPE
Industry Overview
Table 15: European Biotechnology Industry (2010): Number of Biotechnology Product Candidates by Country
Finance Scenario
Table 16: VC Fundings in US and Europe (2010): Percentage Share Breakdown by Indication
Regulatory and Policy Landscape
Current & Future Analysis
Table 17: European Biotechnology Market by Country/Region - France, Germany, Italy, UK, Spain and Rest of Europe - With Annual Revenues in US$Million for Years 2010 through 2015
Table 18: European Biotechnology Market (2011 & 2015): Percentage Breakdown of Value Sales by Country/Region
Table 19: Number of Public Biotechnology Companies in Europe by Country (2010)

3a. DENMARK

3b. FRANCE
Overview
French Government Takes Active Measures to Boost Financing
Challenges and Outlook

3c. GERMANY
Overview
Government Support

3d. ITALY
Overview

3e. THE NETHERLANDS
Market Prospects

3f. POLAND
Overview
Market Access Regulations

3g. UNITED KINGDOM
Agricultural Biotechnology
Impact of Financial Crisis and Outlook

3h. SWEDEN
Overview

3i. SWITZERLAND
Overview

3j. SPAIN

4. ASIA-PACIFIC
Overview

4a. AUSTRALIA
Overview

4b. NEW ZEALAND
Overview
Biotech Companies Attract
Investments from Asia
Government Support

4c. CHINA
Pharmaceutical Segment Dominates Chinese Biotech Market
Table 20: Chinese Biopharmaceutical Market (2010): Funds Raised by IPOs

4d. INDIA
Market Overview
Table 21: Indian Biotechnology Market (2010): Percentage Breakdown of Value Sales by Segment - Biopharma, Bioagri, Bioservices, Bioindustry and Bioinformatics
Booming Biotechnology Industry
Exports - A Major Market for Indian Biotech Industry
Bioinformatics Market to Grow Exponentially in India
Bio-pharma Drives Growth in Biotech Industry
Overview of the Biosimilars Sector
Personalized Medicine - An Emerging Field
A Growing Hub for Clinical Trials and R&D
M&A Scenario Remains Strong
Select Corporate Developments in India (2010)
Transformation - Creating a Platform for Future Growth in Biotech Industry
Regulatory Environment in India
Challenges

4e. MALAYSIA
Overview of Malaysian Biotechnology Industry
Role of National Biotechnology Directorate (Biotek)

4f. SOUTH KOREA
Biotechnology Industry Overview

4g. TAIWAN

4h. SINGAPORE
Overview
Singapore Biotech Start-ups Face Funding Challenges

5. OTHER MARKETS

5a. ARGENTINA

5b. BRAZIL
Industry Outlook
Government Support Spurs Biotech Industry
End-Use Industries
Diagnostics
Biopharmaceuticals
Biotechnology and Animal Health
Agricultural Biotechnology
Environmental Biotechnology
Biotechnology in Food Processing

5c. ISRAEL


GLOBAL DIRECTORY

Biotechnology industry was adversely affected by the global financial crisis, with several leading biotechnology companies in the US and Europe reporting fall in revenues amid restricted capital inflows, and project cancellations and delays. The industry however recovered strongly from the crisis with a number of major biotechnology companies registering profits largely due to the adoption of new efficiency and cost-saving measures. Improving economic conditions also led to an increase in funding for the industry, although majority of this capital was raised by a few leading companies. A number of smaller companies continue to face problems in raising funds for R&D purposes. The funding scenario is unlikely to change drastically in the near term future, as venture capitalists continue to adopt cautious approach to ensure risk-free investments.

The global biotech industry is led by the US, followed by advanced European countries such as the UK, France, Spain and Germany. Developing countries, especially India and China, are forecast to emerge as major agricultural and industrial biotechnology markets owing to rapid increase in population and income levels. The two countries are emerging as key markets for biotech drugs due to their rich talent pool and low cost of investment. Several biotechnology research centers are expected to be set up in developing regions to address impending problems such as growing need for drought and heat-resistant agricultural crops, clean water and low carbon energy. However, inadequate patent protection remains a major hurdle facing biotech drug makers in developing countries. Nevertheless, the governments of these countries are working towards enhancing their patent protection mechanisms.

Healthcare reform legislation, development of flexible/adaptive clinical trial designs and medical device and pharmaceutical taxes are expected to influence the global biotechnology market. The industry is expected to register healthy growth driven by improving healthcare infrastructure, higher involvement of private companies and developments in information technology. The industry is also expected to witness increase in mergers and acquisitions due to the patent expiration of several blockbuster drugs and introduction of newer healthcare regulations that are aimed at controlling costs. Smaller biotechnology firms would seek to divest their businesses to larger companies or enter into in-licensing collaborations and partnerships with cash-rich large companies owing to limited capital availability. Efficacy and safety regulatory policies, technological developments, human resources, public acceptance, human resources, intellectual property, business models and market structure are also expected to influence growth of biotechnology markets in future.

Biotechnology applications have increased manifold in recent years. Presently agriculture, food, health, medical and environmental sciences are the major end-use sectors. Human health dominates the biotechnology field followed by agriculture and industrial applications. Majority of the biotech investments are directed towards discovery of new drugs and therapies. Cardiology, oncology and inflammation constitute the major focus areas for biotech drug companies. Other therapeutic categories include diabetes, hormone treatment using human growth hormone and follicle stimulating hormones, antiviral antibody, anemia and other human enzymes and catalysts.

Global Industry Analysts ©

- Abbott
- Abraxis BioScience
- Actelion,
- Aldurazyme
- Amgen
- Amylin Pharmaceuticals
- Aranesp
- AstraZeneca
- Avastin
- Aventis Group
- Benefix,
- Biogen Idec
- CSL,
- Celera Genomics
- Celgene
- Cephalon
- Chiron
- CuraGen
- Elan
- Eli Lilly
- Enbrei
- Enbrel
- Epogen
- Eprex
- Erbitux,
- Factors Novoseven
- Genentech
- Genzyme
- Gilead Sciences
- GlaxoSmithKline
- Gonal-F
- Herceptin
- Human Genome Sciences
- Humira
- ImClone Systems
- Incyte
- Johnson & Johnson
- Kogenate
- Lantus
- Lexicon Genetics,
- MGI
- MabThera/Rituxan
- Maxygen,
- MedImmune
- Merck
- Millennium Pharmaceuticals
- Myriad Genetics
- Neo-Recormon
- Neulast
- Neulasta
- Neupogen
- Neutrogin
- Novartis
- Novo Nordisk
- OSI Pharmaceuticals
- PDL BioPharma
- Pegintron
- Pfizer
- Pharma
- Procrit
- Puregon
- Rebif
- Refacto
- Remicade
- Rituxan
- Roche
- Roche Genentech
- Sanofi-Aventis
- Serono
- UCB SA
- Wyeth

Order Online - visit http://www.researchandmarkets.com/reports/1582661

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.